Companies ›Healthcare ›EYPT

EYPT — Nasdaq Pharmaceuticals

EyePoint, Inc.

$12,42

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

1,1M USD

P/E

—

EV / Rev

-7,1x

Div yield

—

Op margin

-776,0 %

ROE

-100,6 %

Net margin

-739,4 %

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$13,04

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

EyePoint, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes therapies for eye diseases, generating revenue primarily through product sales and royalty arrangements.

Business. EyePoint, Inc. (EYPT) is a pharmaceutical company headquartered in the United States that operates within the healthcare sector. The firm focuses on the development and commercialization of ophthalmic therapies, primarily generating revenue through product sales. EyePoint is publicly traded on the Nasdaq stock exchange under the ticker symbol EYPT. Specific operating segments and geographic revenue breakdowns are not disclosed in the available data.

Classification66 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

Industry groupPharmaceuticals

Generated · model-assisted

Sell-side consensus

BUY14 analysts

14 buy0 hold0 sell

Avg 12m price target40,50

Analyst recommendations

14 analysts · consensus Buy

Buy14

Hold0

Sell0

12-month price target

40,50

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

14 analysts · indicative

Ownership→

JANUS HENDERSON GROUP PLC

largest disclosed fund holder

Profitability→

-100,6 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning EYPT.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to EYPT. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

EyePoint, Inc. (EYPT) is a pharmaceutical company headquartered in the United States that operates within the healthcare sector. The firm focuses on the development and commercialization of ophthalmic therapies, primarily generating revenue through product sales. EyePoint is publicly traded on the Nasdaq stock exchange under the ticker symbol EYPT. Specific operating segments and geographic revenue breakdowns are not disclosed in the available data.

Classification66 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

Industry groupPharmaceuticals

AI synthesis

GENERATED

EyePoint maintains a strong liquidity position with $77.7 million in cash and equivalents and $144.8 million in marketable securities, totaling $222.5 million in liquid assets [doc:10-Q false --12-31 Q1 0001314102 http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent http://fasb.org/srt/2025#ChiefExecutiveOfficerMember http://fasb.org/us-gaap/2025#AccountsPayableCurrent http://fasb.org/us-gaap/2025#AccountsPayableCurrent 0001314102 eypt:AniPharmaceuticalsIncMember eypt:ProductRightsAgreementMember 2024-10-01 2024-12-31 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001314102 eypt:AniPharmaceuticalsIncMember eypt:LicenseAndCollaborationAgreementMember 2026-01-01 2026-03-31 0001314102 eypt:WatertownMassachusettsMember 2026-02-13 2026-02-13 0001314102 eypt:AltasciencesCompanyIncMember 2026-03-31 0001314102 eypt:TwoThousandTwentyThreeIncentivePlanMember 2025-06-17 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001314102 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001314102 eypt:WatertownMassachusettsMember 2026-02-13 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001314102 us-gaap:RestrictedStockUnitsRSUMember eypt:TwoThousandSixteenAndTwoThousandTwentyThreeIncentivePlanMember 2025-12-31 0001314102 eypt:OcumensionTherapeuticsMember us-gaap:ProductMember 2025-01-01 2025-03-31 0001314102 us-gaap:MoneyMarketFundsMember us-gaap:CreditConcentrationRiskMember eypt:InvestmentInstrumentsMember 2025-01-01 2025-12-31 0001314102 eypt:MaMember eypt:NewPremisesMember srt:MinimumMember 2023-01-23 0001314102 us-gaap:RetainedEarningsMember 2024-12-31 0001314102 us-gaap:RoyaltyMember 2026-01-01 2026-03-31 0001314102 eypt:ProductRightsAgreementAndTheSupplyAgreementMember us-gaap:ProductMember 2026-01-01 2026-03-31 0001314102 eypt:AltasciencesCompanyIncMember 2025-12-31 0001314102 eypt:TwoThousandSixteenIncentivePlanMember 2025-06-17 0001314102 eypt:EquityIncentivePlansMember 2026-01-01 2026-03-31 0001314102 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001314102 eypt:NewPremisesMember eypt:NorthbridgeMassachusettsMember 2023-01-23 2023-01-23 0001314102 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001314102 2024-12-31 0001314102 eypt:TwoThousandTwentyThreeIncentivePlanMember 2025-06-18 2025-06-18 0001314102 eypt:TwoThousandSixteenAndTwoThousandTwentyThreeIncentivePlanMember srt:MaximumMember 2026-01-01 2026-03-31 0001314102 2026-05-01 0001314102 us-gaap:RestrictedStockUnitsRSUMember eypt:TwoThousandSixteenAndTwoThousandTwentyThreeIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2026-01-01 2026-03-31 0001314102 eypt:MaMember 2023-01-23 2023-01-23 0001314102 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001314102 eypt:MaMember 2024-04-01 2024-06-30 0001314102 eypt:EquityIncentivePlansAndInducementAwardGrantsMember 2025-01-01 2025-12-31 0001314102 eypt:FifthAmendmentLeaseMember 2025-01-01 2025-03-31 0001314102 eypt:EquityIncentivePlansAndInducementAwardGrantsMember 2025-12-31 0001314102 us-gaap:StockCompensationPlanMember 2026-01-01 2026-03-31 0001314102 eypt:RoyaltyPurchaseAgreementMember eypt:SWKFundingLLCMember 2025-01-01 2025-03-31 0001314102 2024-04-18 2024-04-18 0001314102 2025-03-31 0001314102 eypt:TwoThousandSixteenAndTwoThousandTwentyThreeIncentivePlanMember srt:MinimumMember 2026-01-01 2026-03-31 0001314102 eypt:TwoThousandTwentyThreeIncentivePlanMember 2023-06-20 0001314102 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001314102 us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001314102 us-gaap:CommonStockMember 2024-12-31 0001314102 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001314102 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001314102 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-12-31 0001314102 us-gaap:ResearchAndDevelopmentExpenseMember 2026-01-01 2026-03-31 0001314102 eypt:OcumensionTherapeuticsMember us-gaap:ProductMember 2026-01-01 2026-03-31 0001314102 eypt:SWKFundingLLCMember eypt:RoyaltyPurchaseAgreementMember 2025-03-18 0001314102 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001314102 us-gaap:MoneyMarketFundsMember us-gaap:CreditConcentrationRiskMember eypt:InvestmentInstrumentsMember 2026-01-01 2026-03-31 0001314102 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember eypt:USAgencySecuritiesMember 2025-12-31 0001314102 2025-12-31 0001314102 2025-01-01 2025-03-31 0001314102 2025-03-18 0001314102 eypt:LicenseAndCollaborationAgreementMember 2025-01-01 2025-03-31 0001314102 eypt:TwoThousandTwentyThreeIncentivePlanMember 2025-06-18 0001314102 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001314102 eypt:AtTheMarketOfferingMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001314102 us-gaap:RetainedEarningsMember 2026-03-31 0001314102 eypt:AniPharmaceuticalsIncMember eypt:ProductRightsAgreementMember srt:MaximumMember 2026-01-01 2026-03-31 0001314102 eypt:FifthAmendmentLeaseMember eypt:WatertownMassachusettsMember 2025-03-31 0001314102 eypt:PerformanceOptionsMember 2026-01-01 2026-03-31 0001314102 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001314102 us-gaap:GeneralAndAdministrativeExpenseMember 2025-0

Key takeaways

EyePoint, Inc. (EYPT) is a pharmaceutical company headquartered in the United States that operates within the healthcare sector.
The firm focuses on the development and commercialization of ophthalmic therapies, primarily generating revenue through product sales.
EyePoint is publicly traded on the Nasdaq stock exchange under the ticker symbol EYPT.
Specific operating segments and geographic revenue breakdowns are not disclosed in the available data.

Bull / Bear case

Generated · model-assisted

BULL CASE · 5

Analysts project 204.5% upside to a mean price target of $40.50, reflecting strong buy consensus among 14 analysts.

The company maintains a low leverage band with a debt-to-equity ratio of 0.19 and a robust current ratio of 8.88.

Liquidity and credit risks are assessed as low, providing a stable financial foundation despite ongoing operational losses.

Cash conversion metrics rank above the pharmaceutical cohort median, indicating relatively efficient cash management compared to peers.

The debt-to-equity ratio of 0.0 places the company in the top quartile for leverage discipline within its peer group.

BEAR CASE · 4

Revenue declined with a negative 3.0% CAGR from FY2023 to FY2025, signaling weak top-line growth momentum.

Operating losses widened significantly to $243.4 million in FY2025, demonstrating deteriorating profitability and expanding cost structures.

Free cash flow turned deeply negative at -$243.4 million in FY2025, highlighting substantial capital consumption and burn rate.

Net and operating margins rank in the bottom quartile of the pharmaceutical cohort, indicating poor relative profitability.

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-03-31

Q4 2025 · Quarter highlights

Revenue $696.0k; Operating income -$87.2M.

Revenue$696.0k

Operating income-$87.2M

Net income-$84.8M

Free cash flow-$81.5M

EPS—

Operating cash flow-$80.5M

Financials

Income statement

Revenue$696.0k

Gross profit—

Operating income-$87.2M

Net income-$84.8M

Margins

Gross margin—

Operating margin-12532.5%

Net margin-12188.5%

FCF margin-11716.4%

Balance sheet

Total assets$288.2M

Total liabilities$57.7M

Total equity$230.5M

Cash & equivalents$77.7M

Long-term debt—

Cash flow

Operating cash flow-$80.5M

CapEx$997.0k

Free cash flow-$81.5M

SBC$11.6M

P&L flow · revenue → net income

Highlights

▍Revenue $696.0k
▍Operating income -$87.2M
▍Net margin -12188.5%

Valuation FY

Market price

$12,42

Market cap

$1.1M

Enterprise valueⓘ

-$221.4M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

-7.1x

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

0.0x

P / Tangible bookⓘ

0.0x

Tangible book

$230.5M

Net cashⓘ

$222.5M

Current ratioⓘ

6.7

Debt / equityⓘ

—

ROAⓘ

-80.5%

ROEⓘ

-1.0%

Cash conversionⓘ

104.0%

CapEx / revenueⓘ

10.5%

SBC / revenueⓘ

88.8%

Dilution ratioⓘ

-99.9%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-3,56

Predicted surprise

-0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-07-18 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-3,56
Revenue	—no estimate	—no estimate	1,9M USD
Operating income	—no estimate	—no estimate	-330,7M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution14 analysts

Strong buy5

Buy9

Hold0

Sell0

Strong sell0

12-month price target$40,50 · Median $36,50

Low $20,00High $68,00

Operating income · consensus-330,7M USD

EPS surprise

+11,0 %

reported vs consensus · beat

Revenue surprise

+1 530,5 %

reported vs consensus · beat

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$20,00

Mean$40,50

Median$36,50

High$68,00

Spot$12,42

+226.1 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskMedium

Liquidity riskLow

Filing-based flags

Source documents mention dilution or offering risk.

Benchmarks vs cohort

Op Margin-776,0 %Bottom quartile

Net Margin-739,4 %Bottom quartile

ROE-100,6 %Bottom quartile

Capex / Rev10,5 %Best in class

D/E0,00Above P75

Cash Conv1,04Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 774 785 sh17 exercises · 14 grants11 insiders

Duker Jay S.Director, President and CEO · Restricted Stock Units → Common StockDisposed 16 667exercise · 2026-07-10
Ribeiro RamiroChief Medical Officer · Stock Option (Right to Buy) → Common StockDisposed 2 438 @ $8,26exercise · 2026-06-30
Ribeiro RamiroChief Medical Officer · Stock Option (Right to Buy) → Common StockDisposed 2 437 @ $8,26exercise · 2026-06-30
Elston GeorgeChief Financial Officer · Restricted Stock Units → Common StockDisposed 7 500exercise · 2026-05-25
Ribeiro RamiroChief Medical Officer · Stock Option (Right to Buy) → Common StockDisposed 2 437 @ $8,26exercise · 2026-04-17
Duker Jay S.Director, President and CEO · Stock Option (Right to Buy) → Common StockDisposed 97 500 @ $20,40other · 2026-03-23
Duker Jay S.Director, President and CEO · Stock Option (Right to Buy) → Common StockDisposed 52 500 @ $13,13other · 2026-03-23
Ribeiro RamiroChief Medical Officer · Stock Option (Right to Buy) → Common StockDisposed 2 438 @ $8,26exercise · 2026-03-04
Ribeiro RamiroChief Medical Officer · Stock Option (Right to Buy) → Common StockDisposed 2 437 @ $8,26exercise · 2026-02-17
Lurker NancyDirector · Restricted Stock Units → Common StockDisposed 75 133exercise · 2026-01-06
Duker Jay S.Director, President and CEO · Restricted Stock Units → Common StockDisposed 20 793exercise · 2026-01-06
Elston GeorgeChief Financial Officer · Restricted Stock Units → Common StockDisposed 15 285exercise · 2026-01-06
Ribeiro RamiroChief Medical Officer · Stock Option (Right to Buy) → Common StockDisposed 29 250 @ $8,26exercise · 2026-01-05
Duker Jay S.Director, President and CEO · Restricted Stock Units → Common StockDisposed 30 000exercise · 2026-01-05
Lurker NancyDirector · Restricted Stock Units → Common StockDisposed 12 666exercise · 2026-01-05
Elston GeorgeChief Financial Officer · Restricted Stock Units → Common StockDisposed 15 000exercise · 2026-01-05
Elston GeorgeChief Financial Officer · Restricted Stock Units → Common StockDisposed 19 667exercise · 2026-01-03
Ribeiro RamiroChief Medical Officer · Restricted Stock Units → Common StockDisposed 19 667exercise · 2026-01-03
Duker Jay S.Director, President and CEO · Restricted Stock Units → Common StockDisposed 65 000exercise · 2026-01-03
Ribeiro RamiroChief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 171 400 @ $17,48grant · 2026-01-02
Ribeiro RamiroChief Medical Officer · Restricted Stock Units → Common StockAcquired 85 700grant · 2026-01-02
Elston GeorgeChief Financial Officer · Restricted Stock Units → Common StockAcquired 63 000grant · 2026-01-02
Duker Jay S.Director, President and CEO · Stock Option (Right to Buy) → Common StockAcquired 331 000 @ $17,48grant · 2026-01-02
Duker Jay S.Director, President and CEO · Restricted Stock Units → Common StockAcquired 165 000grant · 2026-01-02
Duty StuartDirector · Stock Option (Right to Buy) → Common StockAcquired 40 000 @ $17,48grant · 2026-01-02

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Regulatory filings
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data
Reference data

How metrics are computed

Price To Tangible Book
market_price / (tangible_book_value / shares_outstanding_diluted)
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Return On Equity
net_income / total_equity
Enterprise Value
market_cap - net_cash
Ev To Revenue
enterprise_value / revenue
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt

Source documents

EyePoint, Inc. company facts · 2026-07-18
EyePoint, Inc. 10-Q 2026-05-07 · 2026-07-18
EyePoint, Inc. 10-K 2026-03-05 · 2026-07-18
EyePoint, Inc. 10-Q 2025-11-06 · 2026-07-18
EyePoint, Inc. 10-Q 2025-08-07 · 2026-07-18
8-K (sec_8k_material) on EYPT · 2026-07-18
EyePoint Inc Market data — analyst estimates · 2026-07-18
EyePoint Inc Market data — ESG · 2026-07-18
EyePoint, Inc. HA canonical relationships · 2026-07-18

Ownership & reference

Top holders

JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,02 %$46M
Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,02 %$65M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$26M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$88M
AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$5M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$8M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$9M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$9M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$5M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$27M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$14M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$33M
Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$3M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$3M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$1M
Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$1M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$2M
Invesco QQQ TrustFunds · as of 2026-03-310,00 %$2M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$2M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

Leadership

Jay S. DukerPresident, Chief Executive Officer, Director

Insider activity

Net selling1 buys · 8 sellsnet -$2,0M5 insiders · last 365d

Duker Jay S.Director, President and CEO · Common StockOther 8 059 @ $14,72$119K · 2026-07-10
Duker Jay S.Director, President and CEO · Common StockOther 16 667 · 2026-07-10
Ribeiro RamiroChief Medical Officer · Common StockOther 2 437 @ $8,26$20K · 2026-06-30
Ribeiro RamiroChief Medical Officer · Common StockOther 2 438 @ $8,26$20K · 2026-06-30
Ribeiro RamiroChief Medical Officer · Common StockSold 2 437 @ $15,00$37K · 2026-06-30
Ribeiro RamiroChief Medical Officer · Common StockSold 2 438 @ $15,02$37K · 2026-06-30
Elston GeorgeChief Financial Officer · Common StockOther 7 500 · 2026-05-25
Elston GeorgeChief Financial Officer · Common StockOther 3 627 @ $12,93$47K · 2026-05-25
Ribeiro RamiroChief Medical Officer · Common StockOther 2 437 @ $8,26$20K · 2026-04-17
Ribeiro RamiroChief Medical Officer · Common StockSold 2 437 @ $15,00$37K · 2026-04-17
Duker Jay S.Director, President and CEO · Common StockOther 76 766 @ $13,11$1,0M · 2026-03-23
Duker Jay S.Director, President and CEO · Common StockBought 1 500 @ $13,15$20K · 2026-03-16
Ribeiro RamiroChief Medical Officer · Common StockSold 2 438 @ $17,87$44K · 2026-03-04
Ribeiro RamiroChief Medical Officer · Common StockOther 2 438 @ $8,26$20K · 2026-03-04
Elston GeorgeChief Financial Officer · Common StockOther 5 000 · 2026-03-02
Ribeiro RamiroChief Medical Officer · Common StockOther 2 437 @ $8,26$20K · 2026-02-17
Ribeiro RamiroChief Medical Officer · Common StockSold 2 437 @ $15,00$37K · 2026-02-17
Lurker NancyDirector · Common StockOther 75 133 · 2026-01-06
Duker Jay S.Director, President and CEO · Common StockOther 10 054 @ $16,86$170K · 2026-01-06
Elston GeorgeChief Financial Officer · Common StockOther 15 285 · 2026-01-06
Elston GeorgeChief Financial Officer · Common StockOther 4 487 @ $16,86$76K · 2026-01-06
Duker Jay S.Director, President and CEO · Common StockOther 20 793 · 2026-01-06
Lurker NancyDirector · Common StockOther 12 666 · 2026-01-05
Elston GeorgeChief Financial Officer · Common StockOther 4 403 @ $17,43$77K · 2026-01-05
Elston GeorgeChief Financial Officer · Common StockOther 15 000 · 2026-01-05

Short positioning

16.4Mshares short+8.7% vs prior

10.33days to cover

51.2%short of daily vol

79.9Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

EYPTCanonical

Nasdaq · USD

Intel & risk

PredictorBeat prob45 %Surprise-0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskMedium

Liquidity riskLow

Source documents mention dilution or offering risk.

Evidence & claims

From filings & derived data

Total operating expenses (annual): USD 274.81MUnknown
EPS (diluted) (annual): USD-PER-SHARES -3Unknown
Pre-tax income (annual): USD -231.68MUnknown
Net income (annual): USD -231.96MUnknown
EPS (basic) (annual): USD-PER-SHARES -3Unknown
Operating cash flow (annual): USD -240.11MUnknown
Revenue (annual): USD 31.37MUnknown
Cash & equivalents (annual): USD 101.82MUnknown
Shareholders' equity (annual): USD 306.11MUnknown
Current liabilities (annual): USD 37.02MUnknown
Current assets (annual): USD 328.65MUnknown
R&D expense (annual): USD 221.04MUnknown
Operating income (annual): USD -243.43MUnknown
Shares outstanding (annual): 82.83MUnknown
Total assets (annual): USD 364MUnknown
Capex (annual): USD 3.28MUnknown
Total liabilities (annual): USD 57.88MUnknown
Shares outstanding (annual): 68.27MUnknown
Total liabilities (annual): USD 81.96MUnknown
Net income (annual): USD -130.87MUnknown
Operating income (annual): USD -145.85MUnknown
Current liabilities (annual): USD 49.05MUnknown
EPS (basic) (annual): USD-PER-SHARES -2Unknown
EPS (diluted) (annual): USD-PER-SHARES -2Unknown

Showing 24 of 34 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-07-18 04:28 UTCFILINGMaterial 8-K

2026-07-10INSIDERDuker Jay S. transacted 16.7k sh — Director, President and CEO

2026-07-10INSIDERDuker Jay S. transacted 8.1k sh — Director, President and CEO ~$119k

2026-07-10INSIDERDuker Jay S. disposed of 16.7k sh Restricted Stock Units — Director, President and CEO

2026-06-30INSIDERRibeiro Ramiro transacted 2.4k sh — Chief Medical Officer ~$20k

2026-06-30INSIDERRibeiro Ramiro sold 2.4k sh — Chief Medical Officer ~$37k

2026-06-30INSIDERRibeiro Ramiro transacted 2.4k sh — Chief Medical Officer ~$20k

2026-06-30INSIDERRibeiro Ramiro disposed of 2.4k sh Stock Option (Right to Buy) — Chief Medical Officer

2026-05-25 00:00 UTCINSIDER3 insider transactions — 2026-05 1 derivative

2026-05-25INSIDERElston George transacted 3.6k sh — Chief Financial Officer ~$47k

2026-05-25INSIDERElston George transacted 7.5k sh — Chief Financial Officer

2026-05-25INSIDERElston George disposed of 7.5k sh Restricted Stock Units — Chief Financial Officer

2026-05-14FILING8-K filing →

2026-05-07FILING10-Q filing →

2026-05-06FILING8-K filing →

2026-04-27FILINGDEF 14A filing →

2026-04-17 00:00 UTCINSIDER3 insider transactions — 2026-04 1 derivative

2026-04-17INSIDERRibeiro Ramiro sold 2.4k sh — Chief Medical Officer ~$37k

2026-04-17INSIDERRibeiro Ramiro transacted 2.4k sh — Chief Medical Officer ~$20k

2026-04-17INSIDERRibeiro Ramiro disposed of 2.4k sh Stock Option (Right to Buy) — Chief Medical Officer

2026-04-13FILING8-K filing →

2026-03-31EARNINGSQuarterly results — Q4 2025 Revenue USD 0.7M · Net USD -84.8M

2026-03-23 00:00 UTCINSIDER8 insider transactions — 2026-03 · net sell $1.0M 3 derivative

2026-03-23INSIDERDuker Jay S. transacted 76.8k sh — Director, President and CEO ~$1.01M

2026-03-23INSIDERDuker Jay S. disposed of 52.5k sh Stock Option (Right to Buy) — Director, President and CEO

2026-03-23INSIDERDuker Jay S. disposed of 97.5k sh Stock Option (Right to Buy) — Director, President and CEO

2026-03-20FILING8-K filing →

2026-03-16INSIDERDuker Jay S. bought 1.5k sh — Director, President and CEO ~$20k

2026-03-05FILING10-K filing →

2026-03-04FILING8-K filing →

2026-03-04INSIDERRibeiro Ramiro transacted 2.4k sh — Chief Medical Officer ~$20k

2026-03-04INSIDERRibeiro Ramiro sold 2.4k sh — Chief Medical Officer ~$44k

2026-03-04INSIDERRibeiro Ramiro disposed of 2.4k sh Stock Option (Right to Buy) — Chief Medical Officer

2026-03-02FILING8-K filing →

Showing the 40 most recent of 69 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread